The in-house staff scientists at Motac span the key preclinical disciplines of pharmacology, molecular biology, anatomy and physiology. This ensures an integrated, multidisciplinary approach to the development of new translational models, the identification and validation of new therapeutic targets and the evaluation and refinement of new therapies.

Our core expertise is in the field of neurodegenerative disorders, particularly Parkinson’s disease, other movement disorders and cognitive disorders. Several of our personnel have been active over decades in research at the highest level into the basic brain mechanisms that mediate the symptoms of Parkinson’s disease and involuntary movement disorders (dyskinesias) and are internationally-recognised authorities in this area. Their research has led directly to the development of novel therapies, such as deep brain stimulation (DBS) that has benefitted many thousands of patients. This extensive practical experience and technical know-how, accumulated over many years working with the in vivo models offered, is unparalleled in the commercial sector.

The Board of Directors has extensive professional financial and legal expertise and wide experience of clinical drug development in major pharmaceutical companies.